

**2026 Colorado Protein Stability Conference  
August 3 – August 6  
Beaver Run Resort  
Breckenridge, Colorado**

**Presented by the University of Colorado  
Center for Pharmaceutical Biotechnology**

**Conference Schedule**

**Monday, August 3**

3:00 pm      Registration Opens

7:00 pm      Opening Reception  
Copper Top II/III

**Tuesday, August 4**

7:00 am      Breakfast  
Copper Top II/III

8:00 am      Welcoming Comments  
Colorado Ballroom

Protein Stability and Dynamics - I  
Colorado Ballroom

8:05 am      Tobin Sosnick  
University of Chicago  
*Should we be surprised that biothermodynamics works so well?*

8:40 am      Lauren Porter  
NIH  
*Fold switching and protein stability*

9:15 am      Rohit Pappu  
Washington University at St. Louis

*Biophysical chemistry of biomolecular condensates*

9:50 am      Coffee Break

Protein Stability and Dynamics - II  
Colorado Ballroom

10:20 am    Nikolay Dokholyan  
University of Virginia  
*Early Molecular Events in Neurodegeneration*

10:55 am    Kayla Sprenger  
University of Colorado  
*Decoding how protein–protein interactions, stability, and conformational dynamics drive pathogenic mechanisms across neurodegenerative and infectious diseases via MD simulations*

11:30 am    Daumantas Matulis  
Vilnius University  
*Stabilization of proteins by small molecule ligands - use for characterization and affinity determination*

12:05 pm    Lunch  
Copper Top II/III

Vaccines, Solid state protein stability, and AAVs  
Colorado Ballroom

2:00 pm      Neil King  
University of Washington  
*Machine learning-enabled antigen and nanoparticle vaccine design*

2:35 pm      Eric Munson  
Purdue University  
*Advanced Characterization Methods for Assessing Stability of Protein Formulations in the Solid State*

3:10 pm      Susumu Uchiyama

Osaka University  
*rAAV as a Heterogeneous Particle Ensemble: Current Understanding of Its Quality Attributes and Relation to Efficacy and Safety*

3:45 pm      Coffee Break

Antibody Optimization and Developability

4:15 pm      Pete Tessier  
University of Michigan  
*Multi-property antibody optimization using machine learning*

4:50 pm      Hristo Svilenov  
Technische Universität München  
*Looking at unconventional antibodies from a developability perspective*

5:25 pm      Tim Menzen  
Coriolis  
*To platform or not to platform: strategic considerations for antibody formulation in early clinical development*

6:00 pm      Colorado Beer Tasting Reception  
Copper Top II/III

**Wednesday, August 5**

7:30 am      Breakfast  
Copper Top II/III

8:30 am      Poster Setup  
Colorado Ballroom

9:00 am      Poster Session  
Colorado Ballroom

9:00 am – 11:00 am      Even-numbered posters presented

11:00 am – 1:00 pm    Odd-numbered posters presented

1:00 pm    Lunch  
Copper Top II/III

**Thursday, August 6**

7:00 am    Breakfast  
Copper Top II/III

8:00 am    Welcoming Comments  
Colorado Ballroom

ADCs and excipients  
Colorado Ballroom

8:05 am    Shouvik Roy  
Merck  
*New challenges in ADC Drug Product Development - awareness and mitigation*

8:40 am    Lea Sorret  
Lonza  
*Integrated Strategies for ADC Development: Ensuring Stability, Scalability, and Safe Administration of ADCs*

9:15 am    Patrick Garidel  
Boehringer Ingelheim  
*A decade of polysorbate degradation research: current status*

9:50 am    Coffee Break

Excipients in Protein Formulations  
Colorado Ballroom

10:20 am    Satish Singh  
Astria Therapeutics  
*How Sweet it is: Revisiting Sucrose and Trehalose as Stabilizers in Protein Formulations*

- 10:55 am Christian Schoeneich  
University of Kansas  
*Near UV and visible light degradation of therapeutic proteins: the role of common excipients*
- 11:30 am Ashutosh Rao  
FDA  
*Scientific and Regulatory perspectives on excipients used in protein formulations*
- 12:05 pm Lunch  
Copper Top II/III

Protein stability, aggregation, and immunogenicity  
Colorado Ballroom

- 2:00 pm Benjamin Walters  
Genentech  
*Bridging Stability and Biophysical Outcomes in Therapeutic Proteins*
- 2:35 pm Joseph Cohen  
Amgen  
*A high threshold of aggregate numbers is needed to induce immunogenic response in vitro, in vivo and in the clinic*
- 3:10 pm Daniela Verthelyi  
FDA  
*Immunogenicity risk assessments: The impact of aggregates and innate immune response modulating impurities*
- 3:45 pm Coffee Break
- Safe and Stable Formulations
- 4:15 pm Parag Kolhe  
Pfizer

*Formulation and Process Considerations for developing  
patient centric drug product dosage forms*

- 4:50 pm      Erica Schlesinger  
                  Seran Bio  
                  *Formulation without Compromise: Dose, Convenience,  
                  Stability*
- 5:25 pm      Christina Vessely  
                  Biologics Consulting  
                  *Protein Drug Stability Assessments: ICH Q1 and Beyond*
- 6:00 pm      Student Poster Awards & Closing Comments  
                  Colorado Ballroom
- 6:10 pm      Closing Reception  
                  Copper Top II/III